ABOUT

Amunix is leveraging our expertise in precision protein engineering to enable the promise of T cell engagers in solid tumors. Our goal is to save cancer patients’ lives through the development and commercialization of breakthrough therapies that harness the immune system.
Learn More

TECHNOLOGY

Amunix has designed the XPAT platform using its longstanding and validated XTEN technology as a mask for T cell engagers (TCEs). When combined with our proprietary protease release sites, we can selectively unleash the potent activity of TCEs in the tumor by taking advantage of the high protease activity in the tumor microenvironment.
Learn More

LATEST NEWS

June, 26, 2019
Amunix Pharmaceuticals Announces the Appointment of Dr. Bryan Irving as Chief Scientific Officer

May 14, 2019
Amunix Expands Executive Team with Appointment of Dr. Mika Derynck as CMO, Dr. Darcy Mootz as CBO, and Yvonne Li as SVP of Finance

January 3, 2019
​Amunix Announces Appointment of Dr. Angie You as Chief Executive Officer and Dr. Rich Heyman as Chairman of the Board of Directors